

ASX Release

Anatara Shareholder Information Session - Perth

BRISBANE & MELBOURNE, 4th June 2019: Anatara Lifesciences Ltd (ASX:ANR) is pleased to invite existing and potential shareholders to attend an information briefing session in Perth to discuss the Company's work in gastrointestinal health and to meet Chief Executive Officer (CEO), Steven Lydeamore.

Over a light lunch, Steve will discuss Anatara's progress in commercialising innovative, evidence-based products for areas of gastrointestinal health where there is significant unmet need. The Company's lead program is focused on the development of a dietary supplement to fill a gap in currently available treatment options for sufferers of gastrointestinal conditions such as Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS), which affects more than 20% of the Australian population.

Shareholder information session details are as follows:

Date: Tuesday 18th June 2019
 Time: 12.30pm – 2.30pm Lunch will be provided
 Venue: Australian Institute of Company Directors (AICD) Business Centre
 Allendale Square, 1/77 St Georges Terrace, Perth, WA 6000

Please kindly register your attendance and any dietary requirements, by Wednesday 12th June 2019 to Hayley van der Meer at hvandermeer@anatara.com.

For more information please contact:

General inquiries	Media inquiries
Steven Lydeamore CEO, Anatara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatara.com	Jane Lowe Managing Director, IR Department +61 (0) 411 117 774 jane.lowe@irdepartment.com.au

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Following the successful licencing of our first product to leading global animal health company, Zoetis Inc, we are now focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.